Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02583490 · ClinicalTrials.gov registry record · Phase 3
Low Pulse Amplitude Focal ECT (LAP Study)
A Phase 3 study, sponsored by Augusta University.
- Completed
- Registry status
- Phase 3
- Development phase
- 11
- Enrollment target
NCT02583490 is a Phase 3 study that has completed, run by Augusta University. The registered enrollment target is 11 participants.
The verdict
NCT02583490, a Phase 3 study, has completed, sponsored by Augusta University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 11 participants
- Enrollment target
Study Summary
This protocol proposes a pilot randomized clinical trial to examine whether Low Pulse Amplitude Focal ECT (LAP) has a more favorable cognitive profile compared to conventional unilateral ECT and that it has similar effects as traditional ECT in reducing suicidality. The study will enroll 10 patients recruited from the Medical College of Georgia (at Georgia Regents University/Augusta University, GRU/AU) as the only site of the study. Eligible participants will be randomly assigned (1:1 ratio) to receive a course of either RUL LAP ECT, or conventional RUL ECT.
Interventions
- DEVICE spectrum 5000Q ECT device (RUL ECT)
- DEVICE spectrum 5000Q ECT device (RUL LAP ECT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-03 |
| Est. Completion | 2018-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02583490
The ClinicalTrials.gov registry entry for NCT02583490 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Augusta University, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which spectrum 5000Q ECT device (RUL ECT) is the first listed.
NCT02583490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02583490 about?
NCT02583490 is a clinical study titled "Low Pulse Amplitude Focal ECT (LAP Study)". This protocol proposes a pilot randomized clinical trial to examine whether Low Pulse Amplitude Focal ECT (LAP) has a more favorable cognitive profile compared to conventional unilateral ECT and that it has similar effects as traditional ECT in reducing suicidality. The study will enroll 10 patients...
What is the current status of trial NCT02583490?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 11 participants. The study started on 2015-03. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02583490?
The interventions under investigation include: spectrum 5000Q ECT device (RUL ECT) (DEVICE), spectrum 5000Q ECT device (RUL LAP ECT) (DEVICE).
Who is sponsoring clinical trial NCT02583490?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.